ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
My pre-workout Natesto experiment - Embrace your natural trough!
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 199763" data-attributes="member: 13851"><p>Doubting the T nasal spray will result in better absorption.</p><p></p><p>The concentration of 4.5% T in Natesto would allow the application of a smaller amount of gel to the nasal cavity improving the absorption and effectiveness.</p><p></p><p>Only blood work will tell what Tmax levels are truly achieved using lower doses of T nasal spray.</p><p></p><p>Post labs?</p><p></p><p></p><p><strong>2.2.4 How were the dose and the dosing regimen of NATESTO for the Phase 3 study and TBM product determined?</strong></p><p><strong></strong></p><p><strong><em>Reference is made to the minutes of the End of Phase 2 (EOP2) meeting held between the Division and the Sponsor on March 14, 2011 (dated May 4, 2011, under IND 70512 in DARRTS). A Phase 2 study, Nasobol-01-2009, examined the efficacy and tolerability of the 3.2% TBS-1 nasal gel formulation. In this study, the results for the 11 mg T BID dose did not meet the Agency‘s principle acceptance criterion for standard T therapies (i.e., at least 75% of subjects should achieve an average total T concentration within the normal range of 300-1,050 ng/dL). <u>In addition, a linear increase in T concentrations with escalating doses was not achieved</u>. </em></strong><em><strong><u>T</u></strong></em><strong><u><strong><em>h</em></strong></u><em><u>e sponsor believed that the lack of a linear increase suggested that T absorption was limited by the inability of the nasal cavity to hold the tested volumes of the 3.2% TBS-1 formulation</u>.</em></strong></p><p><strong><em></em></strong></p><p><strong><em>The dosing regimen selected for the Phase 3 efficacy and safety study (Study TBS-1-2011-03) was based on results from Studies TBS-1-2010-01 and TBS-1-2011-01. <u>Based on the results of Study Nasabol-01-2009, the Sponsor conducted a Phase 2, dose-finding study, TBS-1-2010-01, evaluating higher concentrations of TBS-1 (i.e., 4.0% and 4.5% T w/w) formulations in reduced volumes</u>.</em></strong> <em><strong>Study TBS-1-2010-01 was an open-label, randomized, balanced, 3-treatments (4.0% TID, 4.5% BID, and 4.5% TID), parallel design, dose-finding, PK study of TBS-1 administered intranasally in 22 hypogonadal males (age of 35-73 years). Subjects were randomized to one of the following 3 treatment groups: </strong></em></p><p><em><strong></strong></em></p><p><em><strong> Treatment A (N=8): TBS-1 syringes pre-filled with 125 μL 4.0% gel to deliver 5.0 mg of T per nostril (intranasal) given TID at 9 pm, 7 am, and 1 pm (total dose: 30 mg/day). </strong></em></p><p><em><strong></strong></em></p><p><em><strong> Treatment B (N=7): TBS-1 syringes pre-filled with 150 μL 4.5% gel to deliver 6.75 mg of T per nostril (intranasal) given BID at 9 pm and 7 am (total dose: 27.0 mg/day). </strong></em></p><p><em><strong></strong></em></p><p><strong><em> Treatment C (N=7): TBS-1 syringes pre-filled with 125 μL 4.5% gel to deliver 5.625 mg of T per nostril (intranasal) given TID at 9 pm, 7 am, and 1 pm (total dose 33.75 mg/day).</em></strong></p><p><strong><em></em></strong></p><p><strong><em>TBS-1 was administered for 7 days as per treatment group assignment. On Day 7, subjects for all treatment groups returned to their study centers and underwent a 24-hour PK sample collection after the 9 pm dosing. Total T PK profiles and parameters are presented in Figure 4 and Table 6.</em></strong></p><p></p><p>[ATTACH=full]13831[/ATTACH]</p><p>[ATTACH=full]13832[/ATTACH]</p><p></p><p><strong><em><u>Concentrating TBS-1 from 3.2% to 4.5% T (w/w) allowed for administration of a smaller amount of gel, resulting in improved and consistent absorption of T, and a higher response rate</u> (i.e., achieving serum T average concentration [Cavg] values within the normal range) of subjects using 4.0% T and 4.5% T (w/w) versus 3.2% T (w/w) TBS-1 formulation.</em></strong><em> <strong>Regardless of the concentration of formulation and the dose, approximately 86-88% of the subjects had a total T Cavg within the normal range of 300-1,050 ng/dL.</strong></em><strong> <em><u>Two (2) out of 7 subjects (i.e., Subject 01-005 Cmax = 1,670 ng/dL; Subject 02-006 Cmax = 1,570 ng/dL) who were in the 13.5 mg BID (4.5% w/w) treatment group had a T Cmax > 1,500 ng/dL</u>. While both the BID and TID doses administered in this study had similar Cavg (approximately 400 ng/mL) within the normal range, <u>the 13.5 mg BID (4.5% T w/w) regimen had a Cmax value above the normal range, while the 11.25 mg TID (4.5% T w/w) regimen did not</u>.</em></strong> <strong><em>All 3 treatments also demonstrated expected increases in mean serum DHT and E2 concentrations following TBS-1 administration (data not shown). The major limitation of this study was that it was a parallel study design instead of being a crossover design (that would allow a direct and accurate comparison between treatment groups).</em></strong> <strong><em><u>Modeling and simulation of profiles for 200 subjects based on data from the 22 subjects from Study TBS-1- 2010-01 supported a reduction from 11.25 mg to 11 mg T per dose without compromising efficacy</u>. Reference is made to Dr. LaiMing Lee’s Clinical Pharmacology review dated September 21, 2011, under IND 70512 in DARRTS.</em></strong></p><p><strong><em></em></strong></p><p><em><strong>Study TBS-1-2011-01 was a Phase 1, randomized, crossover study conducted in 12 healthy men (age of 18-28 years), to compare the BA following a single dose of 11 mg T of TBS-1 from a multiple-dose dispenser (i.e., the proposed commercial method of administration) to that following a single dose of 11 mg T of TBS-1 from a prefilled syringe (i.e., the method of administration used in several studies earlier in the TBS-1 development program). A 12-hour baseline T profile was characterized for each subject to determine their endogenous T concentrations. The TBS-1 treatment was administered at 9 pm. A total of 13 blood samples were collected for each subject over a 12-hour post-dose period. Each treatment period was separated by a washout period of at least 6 days.</strong></em></p><p></p><p>[ATTACH=full]13833[/ATTACH]</p><p></p><p><strong><em>As shown in Figure 5, the multiple-dose dispenser had higher AUC(0-12) values compared to those with the prefilled syringe, while also having a higher Cmax. <u>Based on this finding, the sponsor decided to select the multiple-dose dispenser as the proposed commercial method of administration</u>.</em></strong></p><p><strong><em></em></strong></p><p><strong><em>Based on the findings from Studies TBS-1-2010-01 and TBS-1-2011-01, an 11.0 mg T dose of TBS-1 administered as a 22.0 mg T daily dose (i.e., BID dosing) or 33.0 mg T daily dose (i.e., TID dosing) using the multiple-dose dispenser was selected for the Phase 3 efficacy and safety study (Study TBS-1-2011-03).</em></strong></p><p><strong><em></em></strong></p><p><strong><em>Based on the results of the Phase 3 study, TBS-1-2011-03, the final proposed dosing regimen for NATESTO was determined to be 11 mg T TID (i.e., 33 mg/day).</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 199763, member: 13851"] Doubting the T nasal spray will result in better absorption. The concentration of 4.5% T in Natesto would allow the application of a smaller amount of gel to the nasal cavity improving the absorption and effectiveness. Only blood work will tell what Tmax levels are truly achieved using lower doses of T nasal spray. Post labs? [B]2.2.4 How were the dose and the dosing regimen of NATESTO for the Phase 3 study and TBM product determined? [I]Reference is made to the minutes of the End of Phase 2 (EOP2) meeting held between the Division and the Sponsor on March 14, 2011 (dated May 4, 2011, under IND 70512 in DARRTS). A Phase 2 study, Nasobol-01-2009, examined the efficacy and tolerability of the 3.2% TBS-1 nasal gel formulation. In this study, the results for the 11 mg T BID dose did not meet the Agency‘s principle acceptance criterion for standard T therapies (i.e., at least 75% of subjects should achieve an average total T concentration within the normal range of 300-1,050 ng/dL). [U]In addition, a linear increase in T concentrations with escalating doses was not achieved[/U]. [/I][/B][I][B][U]T[/U][/B][/I][B][U][B][I]h[/I][/B][/U][I][U]e sponsor believed that the lack of a linear increase suggested that T absorption was limited by the inability of the nasal cavity to hold the tested volumes of the 3.2% TBS-1 formulation[/U]. The dosing regimen selected for the Phase 3 efficacy and safety study (Study TBS-1-2011-03) was based on results from Studies TBS-1-2010-01 and TBS-1-2011-01. [U]Based on the results of Study Nasabol-01-2009, the Sponsor conducted a Phase 2, dose-finding study, TBS-1-2010-01, evaluating higher concentrations of TBS-1 (i.e., 4.0% and 4.5% T w/w) formulations in reduced volumes[/U].[/I][/B] [I][B]Study TBS-1-2010-01 was an open-label, randomized, balanced, 3-treatments (4.0% TID, 4.5% BID, and 4.5% TID), parallel design, dose-finding, PK study of TBS-1 administered intranasally in 22 hypogonadal males (age of 35-73 years). Subjects were randomized to one of the following 3 treatment groups: Treatment A (N=8): TBS-1 syringes pre-filled with 125 μL 4.0% gel to deliver 5.0 mg of T per nostril (intranasal) given TID at 9 pm, 7 am, and 1 pm (total dose: 30 mg/day). Treatment B (N=7): TBS-1 syringes pre-filled with 150 μL 4.5% gel to deliver 6.75 mg of T per nostril (intranasal) given BID at 9 pm and 7 am (total dose: 27.0 mg/day). [/B][/I] [B][I] Treatment C (N=7): TBS-1 syringes pre-filled with 125 μL 4.5% gel to deliver 5.625 mg of T per nostril (intranasal) given TID at 9 pm, 7 am, and 1 pm (total dose 33.75 mg/day). TBS-1 was administered for 7 days as per treatment group assignment. On Day 7, subjects for all treatment groups returned to their study centers and underwent a 24-hour PK sample collection after the 9 pm dosing. Total T PK profiles and parameters are presented in Figure 4 and Table 6.[/I][/B] [ATTACH type="full"]13831[/ATTACH] [ATTACH type="full"]13832[/ATTACH] [B][I][U]Concentrating TBS-1 from 3.2% to 4.5% T (w/w) allowed for administration of a smaller amount of gel, resulting in improved and consistent absorption of T, and a higher response rate[/U] (i.e., achieving serum T average concentration [Cavg] values within the normal range) of subjects using 4.0% T and 4.5% T (w/w) versus 3.2% T (w/w) TBS-1 formulation.[/I][/B][I] [B]Regardless of the concentration of formulation and the dose, approximately 86-88% of the subjects had a total T Cavg within the normal range of 300-1,050 ng/dL.[/B][/I][B] [I][U]Two (2) out of 7 subjects (i.e., Subject 01-005 Cmax = 1,670 ng/dL; Subject 02-006 Cmax = 1,570 ng/dL) who were in the 13.5 mg BID (4.5% w/w) treatment group had a T Cmax > 1,500 ng/dL[/U]. While both the BID and TID doses administered in this study had similar Cavg (approximately 400 ng/mL) within the normal range, [U]the 13.5 mg BID (4.5% T w/w) regimen had a Cmax value above the normal range, while the 11.25 mg TID (4.5% T w/w) regimen did not[/U].[/I][/B] [B][I]All 3 treatments also demonstrated expected increases in mean serum DHT and E2 concentrations following TBS-1 administration (data not shown). The major limitation of this study was that it was a parallel study design instead of being a crossover design (that would allow a direct and accurate comparison between treatment groups).[/I][/B] [B][I][U]Modeling and simulation of profiles for 200 subjects based on data from the 22 subjects from Study TBS-1- 2010-01 supported a reduction from 11.25 mg to 11 mg T per dose without compromising efficacy[/U]. Reference is made to Dr. LaiMing Lee’s Clinical Pharmacology review dated September 21, 2011, under IND 70512 in DARRTS. [/I][/B] [I][B]Study TBS-1-2011-01 was a Phase 1, randomized, crossover study conducted in 12 healthy men (age of 18-28 years), to compare the BA following a single dose of 11 mg T of TBS-1 from a multiple-dose dispenser (i.e., the proposed commercial method of administration) to that following a single dose of 11 mg T of TBS-1 from a prefilled syringe (i.e., the method of administration used in several studies earlier in the TBS-1 development program). A 12-hour baseline T profile was characterized for each subject to determine their endogenous T concentrations. The TBS-1 treatment was administered at 9 pm. A total of 13 blood samples were collected for each subject over a 12-hour post-dose period. Each treatment period was separated by a washout period of at least 6 days.[/B][/I] [ATTACH type="full"]13833[/ATTACH] [B][I]As shown in Figure 5, the multiple-dose dispenser had higher AUC(0-12) values compared to those with the prefilled syringe, while also having a higher Cmax. [U]Based on this finding, the sponsor decided to select the multiple-dose dispenser as the proposed commercial method of administration[/U]. Based on the findings from Studies TBS-1-2010-01 and TBS-1-2011-01, an 11.0 mg T dose of TBS-1 administered as a 22.0 mg T daily dose (i.e., BID dosing) or 33.0 mg T daily dose (i.e., TID dosing) using the multiple-dose dispenser was selected for the Phase 3 efficacy and safety study (Study TBS-1-2011-03). Based on the results of the Phase 3 study, TBS-1-2011-03, the final proposed dosing regimen for NATESTO was determined to be 11 mg T TID (i.e., 33 mg/day).[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
My pre-workout Natesto experiment - Embrace your natural trough!
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top